Investigational drug · Phase 3
TGRX-326
Also called: once a day
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "TGRX-326"
First trial start
2023
Jan 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TGRX-326", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TGRX-326" as an intervention, largest first.
- TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Shenzhen TargetRx Co., Ltd.Industry
NCT06082635 · 321 participants · Start Dec 14, 2023 · Primary completion Apr 30, 2026
Drug: TGRX-326; Crizotinib · For: Non Small Cell Lung Cancer
Sites: Guangzhou, China
- TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruiting
Shenzhen TargetRx Co., Ltd.Industry
NCT05441956 · 198 participants · Start Apr 23, 2021 · Primary completion Aug 31, 2025
Drug: TGRX-326 · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
- TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruiting
Shenzhen TargetRx Co., Ltd.Industry
NCT05955391 · 164 participants · Start Jan 18, 2023 · Primary completion Dec 29, 2024
Drug: TGRX-326 · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06294561 · 34 participants · Start Mar 4, 2024 · Primary completion May 6, 2024
Drug: Itraconazole+TGRX-326; Efavirenz+TGRX-326 · For: Non Small Cell Lung Cancer
Sites: Nanjing, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06304805 · 24 participants · Start Dec 13, 2023 · Primary completion Jan 12, 2024
Drug: cycle 1: treatment drug; cycle 1: reference drug and 4 more · For: Non Small Cell Lung Cancer
Sites: Bengbu, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06438367 · 6 participants · Start Jun 26, 2024 · Primary completion Jul 8, 2024
Drug: [14C]TGRX-326 · For: Non Small Cell Lung Cancer
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Coverage of short-course TB preventive therapy regime among people living with HIV registered at a public anti-retroviral therapy centre in Western India.
Zala D, Mehta K, Chavda P, et al. · HIV Res Clin Pract 2026
- Effects of H-coil TMS on suicidality in major depression: A secondary analysis of data from a multisite randomized trial comparing accelerated to once-a-day stimulation.
Roth Y, Tendler A, Brink E, et al. · J Affect Disord 2026
- The Epidemiology of HIV and Injection Practices Among People Who Inject Drugs in Nigeria: Results From the 2020 Integrated Biological and Behavioural Surveillance Survey.
Shaw SY, Green K, Ejeckam C, et al. · J Acquir Immune Defic Syndr 2026
- The Effectiveness of Pentoxifylline 10% Topical Gel on the Pressure Ulcer Healing: A Randomized Controlled Clinical Trial.
Tayyebi AA, Soltani R, Pourahmad M, et al. · Int J Low Extrem Wounds 2026
- [Research on the underlying mechanisms of electroacupuncture in improving colonic dysmotility in ulcerative colitis mice based on cyclic nucleotide-gated cation channels].
Li S, Huang Q, Huang Q, et al. · Zhen Ci Yan Jiu 2026
- Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Martiadis V, Raffone F, Cervino A, et al. · J Clin Psychopharmacol 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.